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There has been increasing interest in the interaction of genetic susceptibility and xenobiotic exposures in cancer etiology. Study of gene-
environment interactions may increase our ability to characterize relatively low population risks if a substantial proportion of the population cancer
burden is attributed to high risk among a smaller group of genetically susceptible members. Further, these studies may provide insight into the
mechanism of carcinogenesis, which can help establish the biologic plausibility of an exposure-cancer relationship. Biologic processes important in
tumorigenesis that exhibit substantial interindividual differences may function as susceptibility factors. Potential examples include polymorphic
enzymes, which activate and detoxify procarcinogens and carcinogens (e.g., certain P450 enzymes, N-acetyltransferase [NAT21, glutathione
S-transferase Ml), and variation in the capacity to repair DNA. Biologic assays are now available to evaluate many of these functions at the DNA and
phenotype level and can be readily incorporated into studies of cancer etiology. - Environ Health Perspect 103(Suppl 8):291-295 (1995)
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Introduction
Numerous environmental carcinogens have
been identified through epidemiologic study
and this knowledge has led directly to
approaches to reduce cancer occurrence.
This approach has been most successful for
relatively potent environmental carcinogens
associated with risks ofabout 2-fold or
greater. Becauseoftheobservational charac-
ter ofepidemiologic studies, interpretation
is problematic when risks are much weaker
than this. There is, however, an increasing
need to characterize such carcinogens as we
attempt to reduce the cancer burden
among the general population. Study of
gene-environment interactions may
increase our ability to characterize relatively
low population risks if a substantial pro-
portion ofthe population cancer burden is
attributed to high risk among a smaller
group ofgenetically susceptible members
exposed to the compound under study. In
addition, these studies may provide insight
into the mechanism of carcinogenesis,
which can help establish the biologic plau-
sibility ofan exposure-cancer relationship.
In this paper, we focus on gene alleles
that are common in the population and
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generally considered polymorphisms (i.e.,
the minor allele frequency is > 0.01); prob-
ably associated with relative risks under 10
and, as such, do not exhibit familial pat-
terns ofinheritance; and may be strongly
dependent on exposure to manifest them-
selves (1,2). In contrast, Li (3) has discussed
single gene mutations which were initially
characterized by studies offamilial cancer,
generally present at lower frequencies, and
associated with very high cancer risk (e.g.,
RBI [retinoblastoma], WTI [Wilm's
tumor], p53 [Li-Fraumeni syndrome], and
APC[adenomatous polyposis coli]) (3).
Potential sources ofsusceptibility for
cancer risk include interindividual varia-
tion in enzymes that activate and detoxify
procarcinogens and carcinogens (e.g.,
Phase I enzymes, which catalyze oxidation,
reduction, and hydrolysis reactions, and
Phase II enzymes, which catalyze conjuga-
tion and synthetic reactions), and repair
DNA. The development of assays to
measure these processes and their initial
application in epidemiologic studies has
been extensively reviewed (4-15). Table 1
includes several examples ofthese processes,
which can be studied at either the DNA
level ifthe genetic basis of the polymor-
phism has been characterized, or at the
phenotypic level using assays that reflect
the function ofeither a single gene product
(e.g., N-acetyltransferase, coded by NAT2)




Smoking-associated tumors have provided
a model for the evaluation of potential
genetic risk factors. For example, the
GSTMI gene encodes the cytosolic enzyme
glutathione S-transferase MI, which can
conjugate intermediate metabolites (e.g.,
epoxides) ofseveral compounds, including
polycyclic aromatic hydrocarbons (PAHs)
(17,18) and aflatoxin (19). Deficiency in
this enzyme is caused by inheriting a
homozygous deletion ofthe GSTMI gene
(20-22), which is referred to as the null






CYP1A2 PAHs, heterocyclic/aromatic amines





PAHs, polychlorinated aromatic hydrocarbons. Datafrom(4-16, 18, 19, 21,24, 41, 45, 47, 48, 52, 59-74).
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genotype and is present in about 30 to 70%
of human populations, depending upon
racial group (20,23-25). Several case-
control studies have demonstrated that this
allele confers increased susceptibility for
lung (26-31) and bladder cancer (32-35);
however, equivocal or negative studies have
also been reported [lung: Shields et al.,
unpublished data; (36); bladder: (25-37)].
Bell et al. (33) demonstrated that the
risk ofbladder cancer associated with heavy
tobacco use (i.e., > 50 pack-years) was 3.5
(95% CI = 1.5-8.0) among subjects with
functional GSTMI genotypes and 5.9
(2.6-13) among subjects with the null
genotype (33). Although the interaction
with genotype was not statistically signifi-
cant, the study suggests that there may be
higher smoking-associated bladder cancer
risks for certain subpopulations. Evidence
supporting the biologic plausibility ofthis
association has recently been provided by a
cross-sectional study that showed that smok-
ers with the null GSTMI genotype had
higher urine mutagenic activity than smok-
erswith functional GSTMI genotypes (38).
An extensive bodyofworkhas indicated
that subjects with the slow N-acetylation
phenotype, which is caused by homozygous
mutations in the NAT2 gene, are at
increased risk for bladder cancer compared
with rapid acetylators, particularly among
populations with exposure to aromatic
amines (4); however, this phenotype does
not appear to be a risk factor for bladder
cancer in populations exposed only to ben-
zidine (39). Vineis et al. (40) provided evi-
dence that the slow N-acetylation phenotype
is associated with a greater tendency to form
4-aminobiphenyl hemoglobin adducts,
which provides biologic support for the
observations on bladder cancer risk.
Biomarkers ofgenetic susceptibility are
being incorporated into studies evaluating
cancer risks associated with exposure to
compounds of uncertain carcinogenicity in
humans. For example, meat cooked at high
temperatures contains heterocyclic amines
(HAAs) that are potent mutagens and ani-
mal carcinogens (41). The cancer risk
posed by exposure to HAAs in the diet
may depend upon the extent to which the
compounds are activated by N-oxidation
(carried out by CYP1A2) and acetylation
(thought to be carried out by NAT2)
(42-46). Interindividual variability in
CYP1A2 activity is known to be partially a
result ofinduction by environmental expo-
sures such as cigarette smoking and dietary
exposure to PAHs; however, there also may
be a genetic component (7). Activity of
NAT2 and CYP1A2 can be characterized
by measuring excreted caffeine metabolites
in urine after caffeine consumption, which
can distinguish between slow and rapid
acetylators and N-oxidizers (47). Recently,
Lang et al. (48) evaluated the risk ofHAA
intake (using preference for meat doneness
as a surrogate) in a case-control study of
colon polyps and cancer. The overall risk
associated with eating well-done meat was
2.1 (adjusted for age and metabolic pheno-
types). Compared with subjects with both
slow N-acetylation and slow CYP1A2
activity (slow/slow) who consumed meat
cooked rare or medium, subjects with
slow/slow phenotypes who ate well-done
meat had a 2.1-fold increased risk, while
subjects with rapid/rapid phenotypes who
ate well-done meat had a 6.4-fold increased
risk. Work is continuing to characterize
food cooking practices as related to HAA
exposure (Sinha et al., unpublished data) to
better quantify the interaction of HAA
exposure, polymorphisms in metabolic
enzymes, and cancer risk.
DNA Repair
Although the relationship between sun
exposure and risk of skin cancer is well
established, it has afforded the opportunity
to test potential genetic susceptibility
markers. Athas et al. (16) developed an
assay that uses cultured lymphocytes to
evaluate the capability ofsubjects to repair
ultraviolet-damaged DNA. Wei et al. (49)
applied this assay to a case-control study of
basal cell carcinoma. Overall, there was a
2.8-fold increased risk for basal cell carci-
noma among individuals with a history of
>6 severe sunburns. Using subjects with
<6 severe sunburns with high DNA repair
capability as the comparison group, sub-
jects with .6 severe sunburns with high
repair capability had a nonsignificant 1.9-
fold increased risk for basal cell carcinoma,
while similarly exposed individuals with
low repair capability had a statistically
significant 5.3-fold increased risk (95%
CI =2.04-12.9 adjusted for age and sex).
The ability to repair DNA damage has
also been evaluated as a potential effect
modifier for smoking-associated tumors.
For example, assays have been developed to
detect the in vitro sensitivity of cultured
peripheral lymphocytes to mutagen-
induced chromosomal aberrations, which
are believed to provide an indirect assess-
ment of DNA-repair capability (12). Hsu
et al. (50) developed an assay that quanti-
fies bleomycin-induced chromatid breakage
using cultured lymphocytes from study
subjects. Recently, Wu et al. (51) used this
assay in a case-control study oflung can-
cer. There was an overall 8.8-fold increased
risk oflung cancer associated with smok-
ing, which was strengthened among the
subgroup ofparticipants who were suscep-
tible for bleomycin-induced chromosomal
damage and weakened among subjects who
were not susceptible. For example, the risk
oflung cancer among smokers who did not
form breaks on chromosome 2 was 4.5
(1.6-12.4) (compared with nonsmokers
who did not form breaks), and 12.8
(4.3-38.7) among smokers who did form
breaks. Similar findings were noted for
chromosomes 4 and 5. This assay has also
been used to study susceptibility for pri-
mary malignancies ofthe upper aerodiges-
tive tract (52) and for second malignancies
ofthe head and neck (53).
Methodologic Issues
The case-control design is very efficient for
examining the interaction ofgenetic suscep-
tibility markers and environmental expo-
sures (54), particularly when high quality
exposure data are available from question-
naires or environmental monitoring. There
is a critical need for more valid and reliable
methods ofobtaining data on dietary, envi-
ronmental, and occupational exposure to
carcinogens by questionnaire [Sinha et al.,
unpublished data; (55,56)], particularly
since there may be subtle exposure/gene
interactions, where particular alleles are
associated with greater risk of cancer at
varying levels of exposure to carcinogens
(31,57). These interactions are likely to be
missed ifadequate attention is not given to
exposure assessment.
Ifthe basis ofobserved interindividual
variation in a potential susceptibility factor
has been characterized at the DNA level, it
can be readily studied using DNA collected
from peripheral blood samples, or poten-
tially from less invasive sources of DNA
(e.g., buccal swabs, which collect small
amounts of exfoliated epithelial cells). If a
susceptibility factor has not been character-
ized at the DNA level, then it is necessary
to use an assay that measures the pheno-
typic expression of that variation. Each
assay has its own logistic demands, and
consideration must be given to the extent to
which disease status may potentially influ-
ence such assays. Regardless ofwhich assay
is used, reliability and accuracy ofassays is
critical to any epidemiologic investigation.
Even small degrees ofgenotype or pheno-
type misclassification may have a substantial
impact on risk estimates, particularly when
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the prevalence of the at-risk allele is either
very low or very high (58).
Summary
Although the relevance of interindividual
variability in metabolism and DNA
repair for cancer risk among the general
population is unclear, several studies
support the concept that variation in these
processes, particularly in combination
with exposure to certain types and levels
of carcinogens, may contribute to the
cancer burden. Evaluating these factors
will be an increasingly important goal for
future studies of cancer etiology. These
studies will have the potential to provide
insight into the mechanism ofcarcinogen-
esis in humans, and may increase our abil-
ity to make better estimates of risk for
particular subpopulations.
REFERENCES
1. Greenberg DA. Linkage analysis ofnecessary disease loci versus
susceptibility loci. Am J Hum Genet 52:135-143 (1993).
2. Caporaso N, Goldstein A. Cancer genes: single and susceptibil-
ity: exposing the difference. Pharmacogenetics (in press).
3. Li FP. Identification and management of inherited cancer sus-
ceptibility. Environ Health Perspect 103(Suppl 8):297-300
(1995).
4. Hein DW. Acetylator genotype and arylamine-induced car-
cinogenesis. Biochem Biophys Acta 948:37-66 (1988).
5. Caporaso N, Landi MT, Vineis P. Relevance ofthe metabolic
polymorphisms to human carcinogenesis: evaluation of epi-
demiologic evidence. Pharmacogenetics 1:4-19 (1991).
6. Guengerich FP, Kim D-H, Iwasaki M. Role of human
cytochrome P450IIE1 in the oxidation ofmany low molecular
weight cancer suspects. Chem Res Toxicol 4:168-179 (1991).
7. Kaclubar FF, Butler MA, Kaderlik KR, Chou H-C, Lang NP.
Polymorphisms for aromatic amine metabolism in humans:
relevance for human carcinogenesis. Environ Health Perspect
98:69-74 (1992).
8. Vineis P, Ronco G. Interindividual variation in carcinogen
metabolism and bladder cancer risk. Environ Health Perspect
98:95-99 (1992).
9. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi SI. The
CYPlAI gene and cancer susceptibility. CRC Crit Rev Oncol
Hematol 14:77-87 (1993).
10. McGlynn KA, Buetow KH. Metabolic and H-ras polymor-
phisms in genetic susceptibility. Cancer Bull 46:220-227
(1994).
11. Amos CI. Identifying gene-environment interactions in cancer
etiology. Cancer Bull 46:214-219 (1994).
12. Wiencke JK, Spitz MR. In vitro chromosomal assays of muta-
gen sensitivity and human cancer risk. Cancer Bull 46:238-246
(1994).
13. Hayes RB. Genetic susceptibility and occupational cancer. Med
Lav (in press).
14. Hirvonen A. Genetic factors in individual responses to environ-
mental exposures. J Occup Environ Med 37:37-43 (1995).
15. Rannug A, Alexandrie A-K, Persson I, Ingelman-Sundberg M.
Genetic polymorphism ofcytochromes P450 lA1, 2D6 and
2E1: regulation and toxicological significance. J Occup Environ
Med 37:25-36 (1995).
16. Athas WF, Hedayati M, Matanoski G, Farmer E, Grossman L.
Development and field-test validation of an assay for DNA
repair in circulating human lymphocytes. Cancer Res
51:5786-5793 (1991).
17. Ketterer B. Protective role ofglutathione and glutathione trans-
ferases in mutagenesis and carcinogenesis. Mutat Res
202:343-361 (1988).
18. Robertson IGC, Guthenberg C, Mannervik B, Jernstrom B.
Differences in steroselectivity and catalytic efficiency of three
human glutathione transferases in the conjugation of glu-
tathione with 7,,8a,-dihydroxy-9a,1Oa-oxy-7,8,9,10-tetrahy-
drobenzo(a)pyrene. Cancer Res 46:2220-2224 (1986).
19. Liu YH, Taylor J, Linko P, Lucier GW, Thompson CL.
Glutathione S-transferase u in human lymphocyte and liver:
role in modulating formation of carcinogen-derived DNA
adducts. Carcinogenesis 12:2269-2275 (1991).
20. Seidegard J, Pero RW. The hereditary transmission ofhigh
glutathione transferase activity towards trans-stilbene oxide in
human mononuclear leukocytes. Hum Genet 69:66-68
(1985).
21. Mannervik B, Alin P, Guthenberg C, Jensson H, Tahir MK,
Warholm M, Jornuall H. Identification of three classes of
cytosolic glutathione transferase common to several mam-
malian species: correlation between structural data and enzy-
matic properties. Proc Natl Acad Sci USA 82:7202-7206
(1985).
22. SeidegardJ, Vorachek WR, Pero RW, Pearson WR. Hereditary
differences in the expression of the human glutathione trans-
ferase active on trans-stilbene oxide are due to a gene deletion.
Proc Natl Acad Sci USA 85:7293-7297 (1988).
23. Board P. Biochemical genetics ofglutathione S-transferase in
man. Am J Hum Genet 33:36-43 (1981).
24. Bell DA, Thompson CL, Taylor J, Miller CR, Perera F, Hsieh
LL, Lucier GW. Genetic monitoring ofhuman polymorphic
cancer susceptibility genes by polymerase chain reaction: appli-
cations to glutathione transferase mu. Environ Health Perspect
98:113-117 (1992).
25. Lin HJ, Han C-Y, Bernstein DA, Hsiao W, Lin BK, Hardy S.
Ethnic distribution of the glutathione transferase mu 1-1
(GSTM1) null genotype in 1473 individuals and application to
bladder cancer susceptibility. Carcinogenesis 15:1077-1081
(1994).
26. Seidegard J, Pero RW, Miller DG, Beattie EJ. A glutathione
transferase in human leukocytes as a marker for the susceptibil-
ity to lung cancer. Carcinogenesis 7:751-753 (1986).
27. Seidegard J, Pero RW, Markowitz MM, Roush G, Miller DG,
Beattie EJ. Isoenzyme(s) ofglutathione transferase (class ,u) as a
marker for the susceptibility to lung cancer: a follow up study.
Carcinogenesis 11:33-36 (1990).
28. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett
GJ, Wathen CG, Wolf CR, Spurr NK. Glutathione S-trans-
ferase mu locus: use ofgenotyping and phenotyping assays to
assess association with lung cancer susceptibility. Carcinogenesis
12:1533-1537 (1991).
29. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung
cancer analyzed in terms of combined genotypes ofP450IA1
and mu-class glutathione S-transferase genes. Jpn J Cancer Res
83:866-870 (1992).
30. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Vainio H. The
GSTM1 null genotype as a potential risk modifier for squa-
mous cell carcinoma ofthe lung. Carcinogenesis 14:1479-1481
(1993).
31. Kihara M, Kihara M, Noda K. Lung cancer risk of GSTM1
null genotype is dependent on the extent of tobacco smoke
exposure. Carcinogenesis 15:415-418 (1994).
32. Lafuente A, Pujol F, Carretero P, Villa JP, Cuchi A. Human
glutathione S-transferase pi (GSTpu) deficiency as a marker for
the susceptibility to bladder and larynx cancer among smokers.
Cancer Lett 68:49-54 (1993).
33. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL,
Lucier GW. Genetic risk and carcinogen exposure: a common
inherited defect ofthe carcinogen-metabolism gene glutathione
S-transferase Ml (GSTM1) that increases susceptibility to blad-
der cancer. J Natl Cancer Inst 85:1159-1164 (1993).
34. Daly AK, Thomas DJ, Cooper J, Pearson WR, Neal DE, Idle
Volume 103, Supplement 8, November 1995 293ROTHMANAND HAYES
JR. Homozygous deletion ofgene for glutathione S-transferase
Ml in bladder cancer. Br Med J 307:481-482 (1993).
35. Brockmoller J, Kerb R, Drakoulis N, Staffeldt B, Roots I.
Glutathione S-transferase MI and its variants A and B as host
factors of bladder cancer susceptibility: a case-control study.
Cancer Res 54:4103-4111 (1994).
36. Brockmoller J, Kerb R, Drakoulis N, Nitz M, Roots I.
Genotype and phenotype ofglutathione S-transferase class p
isozymes p an theta in lung cancer patients and controls.
Cancer Res 53:1004-1011 (1993).
37. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK.
Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer.
Carcinogenesis 14:1821-1824 (1993).
38. Hirvonen A, Nylund L, Kociba P, Husgafvel-Pursiainen K,
Vainio H. Modulation of urinary mutagenicity by genetically
determined carcinogen metabolism in smokers. Carcinogenesis
15:813-815 (1994).
39. Hayes RB, Bi W, Rothman N, Braille F, Caporaso N, Feng P,
You X, Yin S, Woosley R, Meyer UA. N-Acetylation pheno-
type and genotype and risk of bladder cancer, in benzidine-
exposed workers. Carcinogenesis 14:675-678 (1993).
40. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar
FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska
G, Tannenbaum SR. Genetically based N-acetyltransferase
metabolic polymorphism and low-level environmental exposure
to carcinogens. Nature 369:154-156 (1994).
41. Adamson RH. Mutagens and carcinogens formed during cook-
ing of foods and methods to minimize their formation. In:
Cancer Prevention (DeVita VT, Hellman S, Rosenberg SA,
eds). Philadelphia:J.B. Lippincott Company, 1990;1-7.
42. Kato R. Metabolic activation of mutagenic heterocyclic aro-
matic amines from protein pyrolysate. CRC Crit Rev Toxicol
16:307-348 (1986).
43. Shimada T, Twasaki M, Martin MV, Guengerich FP. Human
liver microsomal cytochrome P450 enzymes involved in the
bioactivation ofprocarcinogens detected by umu gene response
in Salmonella typhimurium TA 1535/pSK1002. Cancer Res
49:3218-3228 (1989).
44. Snyderwine EG, Battula N. Selective mutagenic activation by
cytochrome P3-450 ofcarcinogenic arylamines found in foods.
J Natl Cancer Inst 81:223-227 (1989).
45. Degawa M, Tanimura S, Agatsuma T, Hashimoto Y.
Hepatocarcinogenic heterocyclic aromatic amines that induce
cytochrome P-448H isozymes, mainly cytochrome P-448H
(P-4501A2), responsible or mutagenic activation ofthe car-
cinogens in rat liver. Carcinogenesis 10:1119-1122 (1989).
46. Flammang TJ, Kadlubar FF. Acetyl coenzyme A-dependent
metabolic activation of N-hydroxy-3,2'-dimethyl-4-amino-
biphenyl and several carcinogenic N-hydroxy arylamines in
re nation to tissue and species differences, other acyl donors, and
arylhydroxamic acid-dependent acyltransferases. Carcinogenesis
7:919-926 (1986).
47. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P,
Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar
FF. Determination of CYP1A2 and NAT2 phenotypes in
human populations by analysis ofcaffeine urinary metabolites.
Pharmacogenetics 2:116-127 (1992).
48. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC,
Hauer-Jensen M, Kadlubar FF. Rapid metabolic phenotypes
for acetyltransferase and cytochrome P4501A2 and putative
exposure to food-borne heterocyclic amines increase the risk for
colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev
3:675-682 (1994).
49. Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman
L. DNA repair and aging in basal cell carcinoma: a molecular
epidemiology study. Proc Natl Acad Sci USA 90:1614 -1618
(1993).
50. Hsu TC, Johnston DA, Cherry LM, Ramkisson D, Schantz SP,
Jessup JM, Winn RJ, Shirley L, Furlong C. Sensitivity to geno-
toxical effects ofbleomycin in humans: possible relationship to
environmental carcinogenesis. IntJ Cancer43:403-409 (1989).
51. Wu X, Hsu TC, Annegers JF, Amos CI, FuegerJJ, Spitz MR.
A case-control studyofnonrandom distribution ofbleomycin-
induced chromatid breaks in lymphocytes oflung cancer cases.
Cancer Res 55:557-561 (1995).
52. Spitz MR, Fueger JJ, Halabi S, Schantz SP, Sample D, Hsu
TC. Mutagen sensitivity in upper aerodigestive tract cancer: a
case-control analysis. Cancer Epidemiol Biomarkers Prev
2:329-333 (1993).
53. Spitz MR, Hoque A, Trizna Z, Schantz SP, Amos CI, Bond
ML, Hong WK, Hsu TC. Mutagen sensitivity as a risk factor
for second malignant tumors following upper aerodigestive
tract malignancies. J Nadl Cancer Inst 86:1681-1684 (1994).
54. Khoury MJ, Beaty TH. Applications of the case-control
method in genetic epidemiology. Epidemiol Rev 16:134-150
(1994).
55. Stewart WF, Stewart PA. Occupational case-control studies: I.
collecting information on work histories and work-related
exposures. AmJ Ind Med 26:297-312 (1994a).
56. Stewart PA, Stewart WF. Occupational case-control studies: II.
Recommendations for exposure assessment. Am J Ind Med
26:313-326(1994).
57. Nakachi K, Imai K, Hayashi S-I, Watanabe J, Kawajiri K.
Genetic susceptibility to squamous cell carcinoma of the lung
in relation to cigarette smoking dose. Cancer Res
51:5177-5180 (1991).
58. Rothman N, Stewart W, Caporaso NE, Hayes RB.
Misclassification ofgenetic susceptibility markers:implications
for case-control studies and cross-population comparisons.
Cancer Epidemiol Biomarkers Prev 2:299-303 (1993).
59. Guengerich FP. Metabolic activation of carcinogens.
Pharmacol Ther 54:17-61 (1992).
60. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE,
McBride OW, Nebert DW. Human CYPlAl gene co-segrega-
tion ofthe enzyme inducibility phenotype and an RFLP. Am J
Hum Genet 48:720-725 (1991).
61. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in
the 5'-flanking region change transcriptional regulation of the
human cytochrome P450IIE1 gene. J Biol Chem 110:559-565
(1991).
62. Shou M, Korzakwa KR, Crespi CL, Gonzalez FJ, Gelboin HV.
The role of 12 cDNA-expressed human, rodent, and rabbit
cytochromes P450 in the metabolism of benzo-[a]-pyrene
trans-7,8-dihidrodiol. Mol Carcinog 10:159-168 (1994).
63. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP,
Yang CS. Hydroxylation ofchlorzoxazone as a specific probe
for human liver cytochrome P450IIE1. Chem Res Toxicol
3:566-573 (1990).
64. Hayashi SI, Watanabe J, Nakachi K, Kawajiri K. Genetic link-
age oflung cancer-associated MspI polymorphisms with amino
acid replacement in the heme binding region of the human
cytochrome P45OIA1 gene. J Biol Chem 110:407-411 (1991).
65. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I,
Ohmachi T, Wakui A, Kanamaru R, Watanabe M. Association
between restriction fragment length polymorphism of the
human cytochrome P450IIE1 gene and susceptibility to lung
cancer. JpnJ Cancer Res 82:254-256 (1991).
66. Watanabe J, Hayashi S, Nakach K, Imai K, Suda Y, Sekine T,
Kawajiiri K. Pst I and Rsa I in complete linkage disequilibrium
at the CYP2E gene. NucleicAcids Res 18:7194 (1990).
67. Duescher RJ, Elfarra AA. Human liver microsomes are efficient
catalysts of1,3-butadiene oxidation: evidence for major roles by
cytochromes P450 2A6 and 2E1. Arch Biochem Biophys
311:342-349 (1994).
68. Ekstrom G, Von Bahr C, Ingelman-Sundberg M. Human liver
microsomal cytochrome P450IIE1: immunological evaluation
of its contribution to microsomal ethanol oxidation, carbon
tetrachloride reduction and NADPH oxidase activity. Biochem
Pharmacol 38:689-692 (1989).
69. Johansson I, Ingelman-Sundberg M. Benzene metabolism by
ethanol-, acetone-, and benzene inducible cytochrome
P450IIE1 in rat and rabbit liver microsomes. Cancer Res
48:5387-5390 (1988).
294 Environmental Health PerspectivesBIOMARKERS OFGENETICSUSCEPTIBILITY
70. Kim RB, O'Shea D, Wilkinson GR. Interindividual variability
of chlorzoxazone G-hydroxylation in men and women and its
relationship to CYP2EI genetic polymorphisms. Clin
Pharmacol Ther 57:645-655 (1995).
71. YooJS, Ishizaki H, Yang CS. Roles ofcytochrome P450IIE1 in
the dealkylation and denitrosation ofN-nitrosodimethylamine
and N-nitrosodiethylamine in rat liver microsomes.
Carcinogenesis 11:2239-2243 (1990).
72. Deguchi T, Mashimo M, Suzuki T. Correlation between
acetylator phenotypes and genotypes of polymorphic
arylamine N-acetyltransferase in human liver. J Biol Chem
265:12757-12760 (1990).
73. GrafT, Broly F, Hoffmann F, Probst M, Meyer UA, Howald
H. Prediction of phenotype for acetylation and for debriso-
quine hydroxylation by DNA-tests in healthy human volun-
teers. EurJ Clin Pharmacol 43:399-403 (1992).
74. Comstock KE, Sanderson BJ, Claflin G, Henner WD. GST1
gene deletion determined by polymerase chain reaction.
NucleicAcids Res 18:3670 (1990).
Volume 103, Supplement 8, November 1995 295